Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Check out FDAs new roster of bulk drug substances being pulled from use in compounding. Youll see BPC 157 and TB 500 among the various peptides added to the list of category 2 substances FDA mulls compounding for peptides previously flagged over safety risks BioSpace RFK Jr. & claimed regenerative peptides like BPC 157 The Niche FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting